Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001057566 | SCV005901543 | uncertain significance | Pitt-Hopkins syndrome | 2025-02-28 | reviewed by expert panel | curation | The highest population minor allele frequency of the p.Met450Thr variant in TCF4 in gnomAD v4.1.0 is 0.00001 in African/African American and European (Non-Finnish) populations (not sufficient to meet BS1 criteria). The p.Met450Thr variant is observed in at least 1 unaffected individual (internal data, LabCorp Genetics Inc.) (BS2_Supporting). Computational prediction analysis tools are inconclusive for this variant (REVEL gives a score of 0.523). In summary, the p.Met450Thr variant in TCF4 is classified as a Variant of Uncertain Significance based on the ACMG/AMP criteria (BS2_Supporting). (TCF4 Specifications v3.0; curation approved on 02/28/2025). |
Labcorp Genetics |
RCV001057566 | SCV001222065 | benign | Pitt-Hopkins syndrome | 2023-12-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002553836 | SCV003552410 | uncertain significance | Inborn genetic diseases | 2021-01-12 | criteria provided, single submitter | clinical testing | The c.1349T>C (p.M450T) alteration is located in exon 15 (coding exon 14) of the TCF4 gene. This alteration results from a T to C substitution at nucleotide position 1349, causing the methionine (M) at amino acid position 450 to be replaced by a threonine (T). The in silico prediction for the p.M450T alteration is inconclusive. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |